Cancer epigenetics: an introduction
- PMID: 25421652
- DOI: 10.1007/978-1-4939-1804-1_1
Cancer epigenetics: an introduction
Abstract
Epigenetic and genetic alterations contribute to cancer initiation and progression. Epigenetics refers to the study of heritable changes in gene expression without alterations in DNA sequences. Epigenetic changes are reversible and include key processes of DNA methylation, chromatin modifications, nucleosome positioning, and alterations in noncoding RNA profiles. Disruptions in epigenetic processes can lead to altered gene function and cellular neoplastic transformation. Epigenetic modifications precede genetic changes and usually occur at an early stage in neoplastic development. Recent technological advances offer a better understanding of the underlying epigenetic alterations during carcinogenesis and provide insight into the discovery of putative epigenetic biomarkers for detection, prognosis, risk assessment, and disease monitoring. In this chapter we provide information on various epigenetic mechanisms and their role in carcinogenesis, in particular, epigenetic modifications causing genetic changes and the potential clinical impact of epigenetic research in the future.
Similar articles
-
Epigenetic modifications in cancer.Clin Genet. 2012 Apr;81(4):303-11. doi: 10.1111/j.1399-0004.2011.01809.x. Epub 2011 Dec 8. Clin Genet. 2012. PMID: 22082348 Free PMC article. Review.
-
Cancer epigenetics.CA Cancer J Clin. 2010 Nov-Dec;60(6):376-92. doi: 10.3322/caac.20085. Epub 2010 Oct 19. CA Cancer J Clin. 2010. PMID: 20959400 Review.
-
Introduction: epigenetics and cancer.Adv Genet. 2010;70:1-23. doi: 10.1016/B978-0-12-380866-0.60001-0. Adv Genet. 2010. PMID: 20920743
-
Discovery and development of DNA methylation-based biomarkers for lung cancer.Epigenomics. 2014 Feb;6(1):59-72. doi: 10.2217/epi.13.81. Epigenomics. 2014. PMID: 24579947
-
Epigenetic biomarkers for human cancer: the time is now.Crit Rev Oncol Hematol. 2008 Oct;68(1):1-11. doi: 10.1016/j.critrevonc.2008.03.001. Epub 2008 Apr 21. Crit Rev Oncol Hematol. 2008. PMID: 18430583 Review.
Cited by
-
ESR1-promoter-methylation status in primary breast cancer and its corresponding metastases.Clin Exp Metastasis. 2018 Oct;35(7):707-712. doi: 10.1007/s10585-018-9935-5. Epub 2018 Sep 1. Clin Exp Metastasis. 2018. PMID: 30173322
-
Pan-Cancer Analysis of the Oncogenic and Prognostic Role of PKM2: A Potential Target for Survival and Immunotherapy.Biomed Res Int. 2023 Feb 21;2023:3375109. doi: 10.1155/2023/3375109. eCollection 2023. Biomed Res Int. 2023. PMID: 36865483 Free PMC article.
-
AID and TET2 co-operation modulates FANCA expression by active demethylation in diffuse large B cell lymphoma.Clin Exp Immunol. 2019 Feb;195(2):190-201. doi: 10.1111/cei.13227. Epub 2018 Nov 13. Clin Exp Immunol. 2019. PMID: 30357811 Free PMC article.
-
Establishing a role for environmental toxicant exposure induced epigenetic remodeling in malignant transformation.Semin Cancer Biol. 2019 Aug;57:86-94. doi: 10.1016/j.semcancer.2018.11.002. Epub 2018 Nov 16. Semin Cancer Biol. 2019. PMID: 30453042 Free PMC article. Review.
-
Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation.Front Cell Dev Biol. 2021 Jun 21;9:664305. doi: 10.3389/fcell.2021.664305. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34235145 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources